BioRestorative Therapies Announces Exclusive Commercial Agreement with Cartessa
MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics, LLC (“Cartessa”), a leading North American based aesthetic company focused on delivering best-in-class technologies and unparalleled end-to-end professional customer support.
The goal of this transformative agreement is to combine BioRestorative’s deep cell-based biologics experience, and formulation and clinical manufacturing expertise, with Cartessa’s extensive professional aesthetics market reach, and marketing and distribution capabilities. BioRestorative also intends to explore the potential of expanding the collaborative relationship into a broader family of commercialized biocosmeceuticals and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA)-approvals in the emerging biocosmeceuticals space.
As part of the exclusive five (5)-year agreement, BioRestorative has agreed to supply pre-set minimum quantities of finished vials of its initial cell-based biologic commercial product to Cartessa annually as private label under Cartessa’s Chronos ExoCR mark. This product, formulated and manufactured by BioRestorative using its cGMP ISO-7 certified clean room, is comprised of a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by BioRestorative to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness.
Read the full press release here.